DE2661031C2 - - Google Patents
Info
- Publication number
- DE2661031C2 DE2661031C2 DE2661031A DE2661031A DE2661031C2 DE 2661031 C2 DE2661031 C2 DE 2661031C2 DE 2661031 A DE2661031 A DE 2661031A DE 2661031 A DE2661031 A DE 2661031A DE 2661031 C2 DE2661031 C2 DE 2661031C2
- Authority
- DE
- Germany
- Prior art keywords
- cyclosporin
- nrrl
- methanol
- chloroform
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/885—Trichoderma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Die vorliegende Erfindung betrifft Cyclosporin C der Formel I, und
ein Verfahren zu dessen Herstellung gemäß den voranstehenden
Patentansprüchen.
Cyclosporin C ist verwendbar zur Herstellung von Diyhdro-cyclo
sporin C. Letztere Verbindung zeichnet sich durch interessante
chemotherapeutische und pharmakologische Eigenschaften aus und
kann daher als Arzneimittel verwendet werden.
Erfindungsgemäß gelangt man zum Cyclosporin C, indem man jeweils
in an sich bekannter Weise Trichoderma polysporum (Link ex Pers.)
Rifai (NRRL 8044) oder Cylindrocarpon lucidum Booth (NRRL 5760)
züchtet und Cyclosporin C aus der Kulturbrühe isoliert. Die
Züchtung erfolgt auf an sich bekannter Weise, indem man vorzugs
weise einen Stamm NRRL 8044 oder einen Stamm NRRL 5760 verwendet
(siehe z. B. DE-OS 24 55 859). Eine Kultur dieser Stämme ist beim
United States Department of Agriculture (Northern Research and
Development Division), Peoria, Ill., USA, deponiert. Cyclosporin C
kann auf chromatographischem Wege isoliert werden als ein gegen
Aspergillus niger aktives Produkt mit polarerer Wirkung als
Cyclosporin A und B (in der DE-OS 24 55 859 werden Cyclosporin A
und B als S 7481/F-1 und S 7481/F-2 bezeichnet)-
In dem nachfolgenden Beispiel, das die Erfindung näher erläutert,
ihren Umfang aber in keiner Weise einschränken soll, erfolgen
alle Temperaturangaben in Celsiusgraden.
Eine durch aerobe Submerszüchtung von Tolypocladium inflatum
Gams, vormals Trichoderma polysporum (Link ex Pers.) Rifai
(NRRL 8044), oder eine durch Züchtung von Cylindrocarpon lucidum
Booth (NRRL 5760) erhaltene Kulturbrühe (400 L) [siehe Beispiel 2
von DE-OS 24 55 859] wurde mit 400 L n-Butylacetat ausgeführt. Nach
Auftrennung in einem Westfalia-Separator wurde die organische
Phase im Vakuum konzentriert, und der Rohextrakt durch 3stufige
Verteilung zwischen Petroläther und Methanol/Wasser (9 : 1)
entfettet. Das anfallende Material löste in Chloroform und
chromatographierte an 4,5 kg Kieselgel 60 "Merck"®, Korngröße
0,2-0,5 mm), wobei Chloroform mit steigenden Anteilen Methanol
als Elutionsmittel diente. Die mit Chlorofom + 1,5% Methanol
erhaltenen Fraktionen enthielten vorwiegend Cyclosporin A und B,
die späteren, mit Chloroform + 3% Methanol eluierten Anteile
vorwiegend Cyclosporin C. Ihr Nachweis in den Eluatfraktionen
erfolgt mit Hilfe der Dünnschichtchromatographie, wobei sie einen
wesentlich niedrigeren Rf-Wert aufweist als die beiden erstge
nannten Substanzen, z. B. auf Silicagel-Fertigfolien "Polygram"®
mit Chloroform-Methanol (95 : 5) als Fließmittel, Rf=0,26 (Rf
von Cyclosporin A: 0,44, von Cyclosporin B: 0,37). Nach Ver
einigung und Eindampfen der Eluatfraktionen, die nach der dünn
schichtchromatographischen Prüfung ganz oder vorwiegend aus
Cyclosporin C bestehen, wird die chromatographische Reinigung
wiederholt. Die Eluatfraktionen werden wie oben im Dünnschicht
chromatogramm auf ihre Zusammensetzung geprüft und diejenigen von
ihnen, die ganz aus Cyclosporin C bestehen, vereinigt und im
Vakuum bei 20-40° zur Trockene verdampft. Den Rückstand
behandelt man nach Lösen in der 10fachen Menge Alkohol mit
5 Gewichtsprozent Aktivkohle, dampft nach dem Abfiltrieren der
Kohle das Filtrat bei 20-40° im Vakuum ein und trocknet den
Rückstand im Hochvakuum bei 55°.
Der letzte Reinigungsschritt besteht darin, daß man den Rück
stand in der 5fachen Menge Äther löst und durch langsames
Zufügen der 30fachen Menge Hexan unter Schütteln die feste
Substanz ausfällt und sie nach Abkühlen des Gemisches auf 0 bis
5° abfiltriert, mit kaltem Hexan wäscht und im Hochvakuum bei
55° trocknet. Aus der 2,5fachen Menge Aceton werden bei -15°
farblose, prismatische Nadeln von kristallinem Cyclosporin C
erhalten.
Smp. 152 - 155°
[α] = - 255° (Chloroform, c = 0,5)
[α] = - 182° (Methanol, c = 0,5)
Smp. 152 - 155°
[α] = - 255° (Chloroform, c = 0,5)
[α] = - 182° (Methanol, c = 0,5)
Claims (2)
1. Cyclosporin C der Formel I
2. Verfahren zur Herstellung von Cyclosporin C der Formel 1 gemäß Anspruch 1,
dadurch gekennzeichnet, daß man jeweils in an sich bekannter
Weise Trichoderma polysporum (Link ex Pers.) Rifai
(NRRL 8044) oder Cylindrocarpon lucidum Booth (NRRL 5760) züchtet und Cyclosporin C aus der Kulturbrühe isoliert.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1419575A CH614931A5 (de) | 1975-11-04 | 1975-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2661031C2 true DE2661031C2 (de) | 1988-05-05 |
Family
ID=4398730
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2661031A Expired DE2661031C2 (de) | 1975-11-04 | 1976-10-23 | |
DE2648121A Expired DE2648121C2 (de) | 1975-11-04 | 1976-10-23 | Dihydro-cyclosporin C, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2648121A Expired DE2648121C2 (de) | 1975-11-04 | 1976-10-23 | Dihydro-cyclosporin C, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel |
Country Status (23)
Country | Link |
---|---|
US (1) | US4108985A (de) |
JP (2) | JPS5259180A (de) |
AT (1) | AT359642B (de) |
AU (1) | AU513538B2 (de) |
BE (1) | BE847941A (de) |
CA (1) | CA1087609A (de) |
CH (2) | CH614931A5 (de) |
DE (2) | DE2661031C2 (de) |
DK (1) | DK148907C (de) |
ES (1) | ES452942A1 (de) |
FI (1) | FI60701C (de) |
FR (2) | FR2330387A1 (de) |
GB (2) | GB1567201A (de) |
IE (2) | IE44750B1 (de) |
IL (1) | IL50836A (de) |
NL (1) | NL7612026A (de) |
NO (1) | NO763667L (de) |
NZ (1) | NZ182496A (de) |
PH (1) | PH14725A (de) |
PT (1) | PT65791B (de) |
SE (2) | SE432247B (de) |
YU (1) | YU270076A (de) |
ZA (1) | ZA766340B (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210581A (en) * | 1975-11-04 | 1980-07-01 | Sandoz Ltd. | Organic compounds |
DE2819094A1 (de) * | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
FR2410658A1 (fr) * | 1977-11-30 | 1979-06-29 | Science Union & Cie | Nouveau produit biologique d'origine fongique, son obtention et son application a la therapeutique |
SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
SE448386B (sv) * | 1978-10-18 | 1987-02-16 | Sandoz Ag | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
US4201771A (en) * | 1979-03-12 | 1980-05-06 | Merck & Co., Inc. | Antibiotic A43F |
JPS5665853A (en) * | 1979-11-01 | 1981-06-03 | Sankyo Co Ltd | Mycoplanesin derivative and its preparation |
EP0034567B1 (de) * | 1980-02-14 | 1984-11-07 | Sandoz Ag | Verfahren zur Totalsynthese von Cyclosporinen und neue Cyclosporine |
US4396542A (en) * | 1980-02-14 | 1983-08-02 | Sandoz Ltd. | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
US4370266A (en) * | 1980-04-07 | 1983-01-25 | Sankyo Company, Limited | Mycoplanecin derivatives and their preparation |
US4384996A (en) * | 1981-01-09 | 1983-05-24 | Sandoz Ltd. | Novel cyclosporins |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
GB8422253D0 (en) * | 1984-09-04 | 1984-10-10 | Sandoz Ltd | Organic compounds |
EP0198026B1 (de) | 1984-10-04 | 1993-08-04 | Sandoz Ag | Monoklonale antikörper gegen zyklosporine |
US4727035A (en) * | 1984-11-14 | 1988-02-23 | Mahoney Walter C | Immunoassay for cyclosporin |
US4764503A (en) * | 1986-11-19 | 1988-08-16 | Sandoz Ltd. | Novel cyclosporins |
US4798823A (en) * | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
ATE95193T1 (de) * | 1987-06-17 | 1993-10-15 | Sandoz Ag | Cyclosporine und deren benutzung als arzneimittel. |
EP0373260B1 (de) * | 1987-06-22 | 1994-03-09 | Merck & Co. Inc. | Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen |
GB8717299D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Peptides |
GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
US5227467A (en) * | 1987-08-03 | 1993-07-13 | Merck & Co., Inc. | Immunosuppressive fluorinated cyclosporin analogs |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
EP0391909B1 (de) * | 1987-09-03 | 1994-08-17 | The University Of Georgia Research Foundation, Inc. | Cyclosporin-augenmittel |
US4914188A (en) * | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
US5236899A (en) * | 1987-11-16 | 1993-08-17 | Merck & Co., Inc. | 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance |
HU203564B (en) * | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
US4943560A (en) * | 1988-04-06 | 1990-07-24 | Regents Of The University Of Minnesota | Solvent system for chronic vascular infusion of hydrophobic drugs |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US7081445B2 (en) * | 1989-02-20 | 2006-07-25 | Novartis Ag | Cyclosporin galenic forms |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
GB8916901D0 (en) | 1989-07-24 | 1989-09-06 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
DE69222150T2 (de) * | 1991-01-25 | 1998-01-15 | Fujisawa Pharmaceutical Co | Prozess zur produktion von cyclosporin-a und/oder c |
ES2065273B1 (es) * | 1993-05-25 | 1995-09-16 | Biogal Gyogyszergyar | Procedimiento para la purificacion de ciclosporina a. |
US5709797A (en) * | 1996-06-05 | 1998-01-20 | Poli Industria Chimica S.P.A. | Method of isolating cyclosporins |
BR9807528A (pt) | 1997-01-30 | 2000-03-14 | Novartis Ag | Composições farmacêuticas isentas de óleo contendo ciclosporina a |
US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
IN188719B (de) * | 1997-09-08 | 2002-11-02 | Panacea Biotec Ltd | |
US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
JP4261049B2 (ja) | 1997-10-08 | 2009-04-30 | アイソテクニカ インコーポレイテッド | 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用 |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
DE69928938T2 (de) | 1998-07-01 | 2006-08-17 | Debiopharm S.A. | Neues cyclosporin mit verbesserter wirkung |
EP2116228A1 (de) * | 2001-10-19 | 2009-11-11 | Isotechnika Inc. | Neuartige Cyclosporinanalog-Mikroemulsionspräkonzentrate |
PL210795B1 (pl) | 2001-10-19 | 2012-03-30 | Isotechnika Inc | Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247 |
US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
EP1809656A4 (de) | 2004-09-29 | 2009-03-25 | Amr Technology Inc | Cyclosporinalkinanaloga und deren pharmazeutische anwendungen |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
US7361636B2 (en) | 2004-10-06 | 2008-04-22 | Amr Technology, Inc. | Cyclosporin alkynes and their utility as pharmaceutical agents |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
WO2008036244A1 (en) * | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
CN102365094A (zh) * | 2009-01-30 | 2012-02-29 | 英安塔制药有限公司 | 用于预防或者治疗肝炎感染的环孢菌素类似物 |
US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8685917B2 (en) * | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8349312B2 (en) * | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US9217015B2 (en) | 2010-07-16 | 2015-12-22 | S&T Global Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
DK2651965T3 (en) | 2010-12-15 | 2019-02-18 | Contravir Pharmaceuticals Inc | CYCLOSPORIN ANALOGUAL MODULES MODIFIED BY AMINO ACID 1 AND 3 |
WO2012145427A1 (en) | 2011-04-18 | 2012-10-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat cancer using cyclosporine and cyclosporine derivatives |
US8906853B2 (en) | 2012-11-28 | 2014-12-09 | Enanta Pharmaceuticals, Inc. | [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection |
RU2016110247A (ru) | 2013-08-26 | 2017-10-02 | Энанта Фармасьютикалс, Инк. | Аналоги циклоспорина для предупреждения или лечения гепатита с |
US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2455859A1 (de) * | 1973-12-06 | 1975-06-12 | Sandoz Ag | Verfahren zur herstellung neuer antibiotika |
-
1975
- 1975-11-04 CH CH1419575A patent/CH614931A5/xx not_active IP Right Cessation
-
1976
- 1976-10-23 DE DE2661031A patent/DE2661031C2/de not_active Expired
- 1976-10-23 DE DE2648121A patent/DE2648121C2/de not_active Expired
- 1976-10-25 ZA ZA00766340A patent/ZA766340B/xx unknown
- 1976-10-26 FI FI763049A patent/FI60701C/fi not_active IP Right Cessation
- 1976-10-26 DK DK483176A patent/DK148907C/da not_active IP Right Cessation
- 1976-10-27 NO NO763667A patent/NO763667L/no unknown
- 1976-10-27 SE SE7611906A patent/SE432247B/xx unknown
- 1976-10-27 US US05/736,106 patent/US4108985A/en not_active Expired - Lifetime
- 1976-10-29 NL NL7612026A patent/NL7612026A/xx not_active Application Discontinuation
- 1976-11-02 JP JP51131314A patent/JPS5259180A/ja active Granted
- 1976-11-02 CA CA264,703A patent/CA1087609A/en not_active Expired
- 1976-11-02 NZ NZ182496A patent/NZ182496A/xx unknown
- 1976-11-02 GB GB45485/76A patent/GB1567201A/en not_active Expired
- 1976-11-02 AU AU19262/76A patent/AU513538B2/en not_active Ceased
- 1976-11-02 IE IE2379/81A patent/IE44750B1/en unknown
- 1976-11-02 GB GB19922/79A patent/GB1567202A/en not_active Expired
- 1976-11-02 IE IE2439/76A patent/IE44749B1/en unknown
- 1976-11-02 PH PH19079A patent/PH14725A/en unknown
- 1976-11-03 AT AT812276A patent/AT359642B/de not_active IP Right Cessation
- 1976-11-03 IL IL50836A patent/IL50836A/xx unknown
- 1976-11-03 PT PT65791A patent/PT65791B/pt unknown
- 1976-11-03 YU YU02700/76A patent/YU270076A/xx unknown
- 1976-11-03 ES ES452942A patent/ES452942A1/es not_active Expired
- 1976-11-03 BE BE172045A patent/BE847941A/xx not_active IP Right Cessation
- 1976-11-04 FR FR7633231A patent/FR2330387A1/fr active Granted
-
1977
- 1977-04-21 FR FR7711993A patent/FR2338251A1/fr active Granted
-
1979
- 1979-06-11 CH CH543479A patent/CH619735A5/de not_active IP Right Cessation
-
1982
- 1982-03-30 SE SE8202039A patent/SE8202039L/sv not_active Application Discontinuation
-
1986
- 1986-09-11 JP JP61215602A patent/JPS6277399A/ja active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2455859A1 (de) * | 1973-12-06 | 1975-06-12 | Sandoz Ag | Verfahren zur herstellung neuer antibiotika |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2661031C2 (de) | ||
DE2941080C2 (de) | ||
DE2819094C2 (de) | ||
US4315929A (en) | Method of controlling the European corn borer with trewiasine | |
DE2463138C2 (de) | Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung | |
US5663374A (en) | Triterpene derivatives of azadirachtin having insect antifeedant and growth inhibitory activity and a process for extracting such compounds from the neem plant | |
DE3521436C2 (de) | ||
DE2303418A1 (de) | Antibiotisch wirksame substanzen sowie verfahren zum isolieren und reinigen biologisch aktiver substanzen | |
AT364454B (de) | Verfahren zur herstellung eines neuen ringpeptids | |
AT364453B (de) | Verfahren zur herstellung eines neuen ringpeptids | |
US4226856A (en) | Preparation and use of bouvardin and deoxybouvardin | |
CH637123A5 (en) | Monocyclic peptide, its preparation and use | |
CH640521A5 (en) | Cyclosporin D | |
AT381102B (de) | Verfahren zur herstellung von neuem isocyclosporin g | |
AT381101B (de) | Verfahren zur herstellung von neuem dihydrocyclosporin g | |
CH544752A (de) | Verfahren zur Herstellung neuer Glucoside | |
EP0054514A1 (de) | Neue antibiotisch wirksame Aminopapulacandin-Derivate | |
CH637124A5 (en) | Antibiotic, its preparation and use | |
CH589716A5 (en) | Antibiotics S 7481-F-1 and 2 - prepd. from new strains of Cylindrocarbon or Trichoderma esp. useful as immunosuppressant | |
FI60718C (fi) | En ny ringpeptid cyklosporin c anvaendbar som mellanprodukt vid framstaellning av dihydrocyklosporin c och ett foerfarande foer dess framstaellning | |
DE2039990C2 (de) | Neue Antibiotika B-5050 A bis F (Maridomycin I bis VI), Verfahren zu ihrer Herstellung und ihre pharmazeutische Zubereitung | |
CH603790A5 (en) | Antibiotics S 7481-F-1 and 2 | |
US3219544A (en) | Process for producing antibiotic | |
DE1593086C3 (de) | Verfahren zur Isolierung von Peruvosid aus Pflanzenmaterialien | |
CH632010A5 (en) | Process for the preparation of a novel antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
Q172 | Divided out of (supplement): |
Ref country code: DE Ref document number: 2648121 |
|
8110 | Request for examination paragraph 44 | ||
AC | Divided out of |
Ref country code: DE Ref document number: 2648121 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition |